About OmerosPipelineInvestorsNews

Investor Relations Home

Due to an error by our third-party webcasting provider, the live webcast on August 9 was disconnected for approximately three minutes during the Q&A segment. However, the complete webcast is available for replay on demand.

Corporate Profile

Here you will find financial reports and shareholder information about Omeros Corporation, including recent news, current and historical share price, and electronic copies of our SEC filings.

Stock Quote
OMER (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) Stock is Down 0.27 (3.20%)
Data as of 10/26/16 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent Press ReleasesMore >>
10/20/16Omeros Announces Positive Data from OMS721 Phase 2 Trial in Patients with Stem Cell Transplant-Associated Thrombotic Microangiopathy
-- Targeted Indications for the Company’s MASP-2 Inhibitor Continue to Expand -- SEATTLE--(BUSINESS WIRE)--Oct. 20, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive results in patients with hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA) from the company's Phase 2 clinical trial of OMS721 in TMAs, with clinically meaningful improvement in measures of red blood cell destruction, specifically ... 
 Printer Friendly Version
10/19/16Omeros Announces Positive Data from Phase 2 Clinical Trial Evaluating PPAR-gamma Agonist in Cocaine Abuse
-- Decreases Craving and Protects Brain White Matter Integrity -- SEATTLE--(BUSINESS WIRE)--Oct. 19, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive results from a Phase 2 clinical trial evaluating the effects of a peroxisome proliferator-activated receptor (PPAR)-gamma agonist in patients with cocaine use disorder (CUD). The trial, designed and conducted by Joy M. Schmitz, Ph.D. and her colleagues at the Center for Neurobehavioral ... 
 Printer Friendly Version
10/17/16Omeros Announces Positive Data from OMS721 Phase 2 Clinical Trial in Renal Diseases
-- Pursuing Breakthrough Therapy Designation in IgA Nephropathy (Berger’s Disease) -- SEATTLE--(BUSINESS WIRE)--Oct. 17, 2016-- Omeros Corporation (NASDAQ: OMER) today announced positive data from the company’s Phase 2 clinical trial of OMS721 for the treatment of kidney disorders, none of which currently have an approved treatment and all of which frequently lead to end-stage renal disease and dialysis. Statistical significance (p ≤ 0.017) wa... 
 Printer Friendly Version
09/08/16Omeros’ MASP-2 Antibody Preserves Brain Tissue and Function in Stroke Models
-- Data Published in Journal of Neuroinflammation -- SEATTLE--(BUSINESS WIRE)--Sep. 8, 2016-- Omeros Corporation (NASDAQ: OMER) today announced results from its OMS721 complement program. OMS721 is Omeros’ lead antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2). In well-established animal models of ischemic brain injury or stroke, MASP-2 deficiency or inhibition significantly limited brain infarct size and protected... 
 Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Featured Report
Download Documentation 2015 Annual Report
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Omeros Corporation posts new information to the site. Just enter your e-mail address and click Submit.

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.